|
|
安罗替尼治疗妇科肿瘤的有效性和安全性：一项荟萃分析
|
Abstract:
目的：妇科肿瘤是严重危害女性健康的疾病。最常见的三种妇科肿瘤包括卵巢癌、宫颈癌和子宫内膜癌。本研究旨在评价安罗替尼治疗妇科肿瘤的疗效和安全性。方法：通过计算机检索PubMed、Cochrane library、Embase、中国知网、万方、维普、Web of Science及中国生物医学文献服务系统数据库检索相关文献。研究终点包括客观缓解率、疾病控制率、中位无进展生存期和不良事件。结果：最终共纳入16项队列研究和20项单臂研究。在疗效方面，在16项队列研究中，安罗替尼可以提高妇科肿瘤的客观缓解率和疾病控制率，结果均有统计学意义(P < 0.05)。在亚组分析中发现卵巢癌和宫颈癌的客观缓解率和疾病控制率相比化疗有所提高。在20项单臂研究中，总客观缓解率为0.353 (95% CI: 0.288~0.417)，总疾病控制率为0.817 (95% CI: 0.790~0.843)，总中位无进展生存期为6.095 (95% CI: 5.131~7.059)。关于安全性，最常见的不良事件包括恶心、疲劳、高血压、手足综合征和白细胞减少症。安罗替尼联合化疗组高血压和手足综合征的发生率高于单独化疗组。结论：本研究表明，安罗替尼在治疗卵巢癌、宫颈癌和子宫内膜癌方面具有显著的疗效和良好的安全性。
Objective: Gynecological tumors, including ovarian, cervical, and endometrial cancers, are serious threats to women’s health. This study aims to evaluate the efficacy and safety of anlotinib in treating these tumors. Methods: We conducted a comprehensive search of PubMed, the Cochrane Library, Embase, CNKI, WANFANG, VIP, Web of Science, and the Chinese BioMedical Literature Database for relevant studies. The primary outcomes included overall response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and adverse events (AEs). Results: A total of 16 cohort studies and 20 single-arm studies were included. In terms of efficacy, anlotinib significantly improved ORR and DCR in gynecological cancer treatment (P < 0.05) across the 16 cohort studies. Subgroup analyses revealed similar improvements in ovarian and cervical cancers. Among the 20 single-arm studies, the pooled ORR was 0.353 (95% CI: 0.288~0.417), the pooled DCR was 0.817 (95% CI: 0.790~0.843), and the pooled mPFS was 6.095 months (95% CI: 5.131~7.059). Regarding safety, common AEs included nausea, fatigue, hypertension, hand-foot syndrome, and leukopenia. The incidence of hypertension and hand-foot syndrome was higher in patients receiving anlotinib plus chemotherapy compared to those receiving chemotherapy alone. Conclusion: This Meta-analysis indicates that anlotinib demonstrates significant efficacy and acceptable safety in treating ovarian, cervical, and endometrial cancers.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [2] | Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763 |
| [3] | Ledermann, J.A. (2018) First-Line Treatment of Ovarian Cancer: Questions and Controversies to Address. Therapeutic Advances in Medical Oncology, 10, 1-8. https://doi.org/10.1177/1758835918768232 |
| [4] | Pujade-Lauraine, E. and Combe, P. (2016) Recurrent Ovarian Cancer. Annals of Oncology, 27, i63-i65. https://doi.org/10.1093/annonc/mdw079 |
| [5] | Tewari, K.S., Sill, M.W., Penson, R.T., Huang, H., Ramondetta, L.M., Landrum, L.M., et al. (2017) Bevacizumab for Advanced Cervical Cancer: Final Overall Survival and Adverse Event Analysis of a Randomised, Controlled, Open-Label, Phase 3 Trial (Gynecologic Oncology Group 240). The Lancet, 390, 1654-1663. https://doi.org/10.1016/s0140-6736(17)31607-0 |
| [6] | Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., et al. (2011) Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. New England Journal of Medicine, 365, 2473-2483. https://doi.org/10.1056/nejmoa1104390 |
| [7] | Han, B., Li, K., Zhao, Y., Li, B., Cheng, Y., Zhou, J., et al. (2018) Anlotinib as a Third-Line Therapy in Patients with Refractory Advanced Non-Small-Cell Lung Cancer: A Multicentre, Randomised Phase II Trial (Alter0302). British Journal of Cancer, 118, 654-661. https://doi.org/10.1038/bjc.2017.478 |
| [8] | Huang, J., Xiao, J., Fang, W., Lu, P., Fan, Q., Shu, Y., et al. (2021) Anlotinib for Previously Treated Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Double‐Blind Randomized Phase 2 Trial. Cancer Medicine, 10, 1681-1689. https://doi.org/10.1002/cam4.3771 |
| [9] | Li, D., Chi, Y., Chen, X., Ge, M., Zhang, Y., Guo, Z., et al. (2021) Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial. Clinical Cancer Research, 27, 3567-3575. https://doi.org/10.1158/1078-0432.ccr-20-2950 |
| [10] | Zhou, A., Bai, Y., Song, Y., Luo, H., Ren, X., Wang, X., et al. (2019) Anlotinib versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. The Oncologist, 24, e702-e708. https://doi.org/10.1634/theoncologist.2018-0839 |
| [11] | 沈小芳, 茹利新, 纪鹏天, 等. 安罗替尼与吉西他滨联合奥沙利铂方案治疗晚期难治性卵巢癌的临床效果及对患者相关指标的影响[J]. 中国妇幼保健, 2024, 39(1): 6-10. |
| [12] | 范仁亮. 安罗替尼联合紫杉醇加卡铂对晚期宫颈癌患者生存时间及睡眠质量的影响[J]. 世界睡眠医学杂志, 2020, 7(12): 2050-2052. |
| [13] | 符小春, 刘秀玲, 王茹娜. 安罗替尼联合TP化疗治疗晚期卵巢癌的疗效观察及对肿瘤干细胞标志物表达的影响[J]. 医药论坛杂志, 2023, 44(24): 34-38. |
| [14] | 胡婷婷. 安罗替尼联合替吉奥治疗铂耐药晚期卵巢癌的疗效和安全性[J]. 东方药膳, 2020(14): 62. |
| [15] | 刘挺, 唐之雅, 郑彩红, 李政星, 李炳君. 安罗替尼联合化疗治疗复发或转移性宫颈癌的临床研究[J]. 中文科技期刊数据库(引文版)医药卫生, 2021(1): 28-30. |
| [16] | 李莉琛, 廖建容, 袁琴, 等. 安罗替尼联合贝伐珠单抗治疗复发转移性宫颈癌的效果[J]. 西北药学杂志, 2024, 39(3): 139-143. |
| [17] | 李文静. 安罗替尼联合TP化疗治疗晚期卵巢癌的疗效观察及对肿瘤标志物的影响[J]. 中国药物评价, 2023, 40(3): 266-270. |
| [18] | 陆小玲, 林华明, 黄毅超, 等. 安罗替尼维持治疗晚期卵巢癌的效果观察[J]. 广州医科大学学报, 2022, 50(4): 65-70. |
| [19] | 潘毅贞, 黄倩羽. 白蛋白结合型紫杉醇联合顺铂、安罗替尼治疗晚期宫颈癌的效果[J]. 吉林医学, 2022, 43(10): 2692-2694. |
| [20] | 孙萍, 褚亮, 赵西侠, 等. 安罗替尼联合盐酸多柔比星脂质体治疗复发铂耐药卵巢癌疗效及对患者肿瘤标志物、凋亡因子水平的影响[J]. 中国妇产科临床杂志, 2023, 24(5): 456-459. |
| [21] | 谭柳, 楚阿兰, 杨瑜, 等. 安罗替尼联合化疗在子宫颈癌进展期患者中的疗效与安全性观察[J]. 实用妇产科杂志, 2022, 38(4): 305-309. |
| [22] | 王乐乐, 白玉勤, 季洪波, 等. 安罗替尼联合依托泊苷二线治疗铂类耐药型晚期卵巢癌的临床研究[J]. 西北国防医学杂志, 2020, 41(6): 361-366. |
| [23] | 王卫东. 靶向治疗对复发性耐药性卵巢癌的疗效分析[J]. 实用妇科内分泌电子杂志, 2022, 9(22): 42-44. |
| [24] | 夏婷婷. 安罗替尼治疗晚期卵巢癌对血清细胞凋亡分子和血管生成因子的影响[J]. 河北医药, 2021, 43(12): 1814-1817. |
| [25] | 徐海波, 徐倩倩, 陆泓. 化疗联合安罗替尼治疗宫颈癌患者的临床效果与安全性分析[J]. 实用妇科内分泌电子杂志, 2022, 9(32): 34-36. |
| [26] | 徐睿哲, 赵培峰. 盐酸安罗替尼联合化疗对宫颈癌患者癌组织血管新生能力及MEK/ERK通路的影响[J]. 中国药物应用与监测, 2024, 21(2): 102-105. |
| [27] | 陈倩, 赵秧, 康马飞, 等. 安罗替尼治疗多线化疗后进展晚期卵巢癌的疗效观察[J]. 中国实用医药, 2020, 15(7): 1-3. |
| [28] | 金惠敏, 林丽红, 赵振, 等. 安罗替尼联合PD-1抑制剂后线治疗晚期上皮性卵巢癌的疗效及安全性分析[J]. 肿瘤防治研究, 2022, 49(10): 1059-1064. |
| [29] | 刘巧珍, 陆超, 周林平, 等. 安罗替尼用于化疗耐药的复发难控卵巢恶性实体肿瘤疗效评价[J]. 药品评价, 2022, 19(1): 57-59. |
| [30] | 唐清清, 莫月媚, 苏震朝, 等. 安罗替尼联合化疗治疗晚期恶性肿瘤的临床观察[J]. 中国处方药, 2021, 19(7): 4-6. |
| [31] | 王娇, 门俊芬, 梁洪陆, 等. 安罗替尼治疗二线及以上化疗失败的铂耐药卵巢癌的疗效观察[J]. 保健文汇, 2022, 23(27): 97-100. |
| [32] | 王军华, 马玫丽, 徐小萌, 等. 安罗替尼一线维持治疗妇科肿瘤的疗效及安全性回顾性研究[J]. 医药论坛杂志, 2024, 45(2): 186-190. |
| [33] | 王雪晴, 张钟月, 赵馨萍, 等. 特瑞普利单抗联合安罗替尼二线以上治疗晚期卵巢癌的临床疗效及不良反应护理观察[J]. 肿瘤基础与临床, 2024, 37(3): 360-364. |
| [34] | 熊星辉, 付陆军, 夏勤. 信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌的临床疗效和安全性研究[J]. 健康之家, 2023(17): 114-116. |
| [35] | 杨萌, 王晶晶, 邓少琼, 等. 安罗替尼联合尼拉帕利治疗铂耐药复发性卵巢癌的疗效及安全性分析[J]. 中华肿瘤杂志, 2024, 46(7): 696-702. |
| [36] | 杨雪晶, 宋东, 杨晓玲, 等. 盐酸安罗替尼治疗晚期恶性肿瘤的安全性及有效性分析[J]. 肿瘤研究与临床, 2020, 32(7): 489-492. |
| [37] | 姚书娜, 姚志华, 严正, 等. 安罗替尼联合依托泊苷口服治疗铂类耐药或难治性晚期卵巢癌的临床疗效观察[J]. 中国医药导刊, 2021, 23(2): 100-103. |
| [38] | 郑爽, 张志强, 王晓舟, 等. 盐酸安罗替尼治疗晚期妇科肿瘤患者的疗效及安全性[J]. 中国医药指南, 2020, 18(22): 45-46+51. |
| [39] | Hong, X., Qiu, S., Wu, X., Chen, S., Chen, X., Zhang, B., et al. (2023) Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study. Drug Design, Development and Therapy, 17, 2025-2033. https://doi.org/10.2147/dddt.s408304 |
| [40] | Li, X., Rao, Y., Sun, B. and Mao, X. (2022) Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study. International Journal of General Medicine, 15, 3977-3989. https://doi.org/10.2147/ijgm.s352536 |
| [41] | Liu, G., Feng, Y., Li, J., Deng, T., Yin, A., Yan, L., et al. (2022) A Novel Combination of Niraparib and Anlotinib in Platinum-Resistant Ovarian Cancer: Efficacy and Safety Results from the Phase II, Multi-Center ANNIE Study. eClinicalMedicine, 54, Article ID: 101767. https://doi.org/10.1016/j.eclinm.2022.101767 |
| [42] | Cui, Q., Hu, Y., Ma, D. and Liu, H. (2021) A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer. Drug Design, Development and Therapy, 15, 339-347. https://doi.org/10.2147/dddt.s286529 |
| [43] | Wei, W., Ban, X., Yang, F., Li, J., Cheng, X., Zhang, R., et al. (2022) Phase II Trial of Efficacy, Safety and Biomarker Analysis of Sintilimab plus Anlotinib for Patients with Recurrent or Advanced Endometrial Cancer. Journal for ImmunoTherapy of Cancer, 10, e004338. https://doi.org/10.1136/jitc-2021-004338 |
| [44] | Wu, Y., Li, P., Zhu, Y., et al. (2023) Effectiveness and Safety of Mono-Anlotinib Mono Therapy or in Combination with Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Center Retrospective Study. American Journal of Translational Research, 15, 1973-1981. |
| [45] | Xu, Q., Wang, J., Sun, Y., Lin, Y., Liu, J., Zhuo, Y., et al. (2022) Efficacy and Safety of Sintilimab plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. Journal of Clinical Oncology, 40, 1795-1805. https://doi.org/10.1200/jco.21.02091 |
| [46] | Zhu, J., Song, C., Zheng, Z., Xia, L., Chen, Y., Ke, G., et al. (2021) Anlotinib in Chinese Patients with Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial. Frontiers in Oncology, 11, Article ID: 720343. https://doi.org/10.3389/fonc.2021.720343 |
| [47] | Viallard, C. and Larrivée, B. (2017) Tumor Angiogenesis and Vascular Normalization: Alternative Therapeutic Targets. Angiogenesis, 20, 409-426. https://doi.org/10.1007/s10456-017-9562-9 |
| [48] | Jain, R.K. (2014) Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell, 26, 605-622. https://doi.org/10.1016/j.ccell.2014.10.006 |
| [49] | Chen, H., Ye, D., Xie, X., Chen, B. and Lu, W. (2004) VEGF, Vegfrs Expressions and Activated Stats in Ovarian Epithelial Carcinoma. Gynecologic Oncology, 94, 630-635. https://doi.org/10.1016/j.ygyno.2004.05.056 |
| [50] | Tomao, S., Tomao, F., Rossi, L., Zaccarelli, E., Caruso, D., Zoratto, F., et al. (2014) Angiogenesis and Antiangiogenic Agents in Cervical Cancer. OncoTargets and Therapy, 7, 2237-2248. https://doi.org/10.2147/ott.s68286 |
| [51] | 周俭珊, 叶红. HIF-1α、VEGF及HIF-1α/VEGF轴在子宫内膜癌中的表达研究进展[J]. 海南医学, 2015(16): 2413-2416. |
| [52] | Itatani, Y., Kawada, K., Yamamoto, T. and Sakai, Y. (2018) Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-Vegf Pathway. International Journal of Molecular Sciences, 19, Article No. 1232. https://doi.org/10.3390/ijms19041232 |
| [53] | Lopes-Coelho, F., Martins, F., Pereira, S.A. and Serpa, J. (2021) Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. International Journal of Molecular Sciences, 22, Article No. 3765. https://doi.org/10.3390/ijms22073765 |
| [54] | Zsiros, E., Lynam, S., Attwood, K.M., Wang, C., Chilakapati, S., Gomez, E.C., et al. (2021) Efficacy and Safety of Pembrolizumab in Combination with Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer. JAMA Oncology, 7, 78-85. https://doi.org/10.1001/jamaoncol.2020.5945 |
| [55] | Alvarez Secord, A., O’Malley, D.M., Sood, A.K., Westin, S.N. and Liu, J.F. (2021) Rationale for Combination PARP Inhibitor and Antiangiogenic Treatment in Advanced Epithelial Ovarian Cancer: A Review. Gynecologic Oncology, 162, 482-495. https://doi.org/10.1016/j.ygyno.2021.05.018 |
| [56] | Tentori, L., Lacal, P.M., Muzi, A., Dorio, A.S., Leonetti, C., Scarsella, M., et al. (2007) Poly(ADP-Ribose) Polymerase (PARP) Inhibition or PARP-1 Gene Deletion Reduces Angiogenesis. European Journal of Cancer, 43, 2124-2133. https://doi.org/10.1016/j.ejca.2007.07.010 |
| [57] | Gao, Y., Liu, P. and Shi, R. (2020) Anlotinib as a Molecular Targeted Therapy for Tumors (Review). Oncology Letters, 20, 1001-1014. https://doi.org/10.3892/ol.2020.11685 |
| [58] | Miller, D.S., Carlson, M., Lea, J., et al. (2022) Phase 2 Study Assessing the Efficacy of Adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to Chemotherapies in Subjects with Platinum Resistant Ovarian Carcinoma. International Journal of Gynecological Cancer, 32, A259. |
| [59] | NCT (2021) A Clinical Study of TQB2450 Injection Combined with Anlotinib Hydrochloride Capsules versus Paclitaxel as Weekly Treatment of Relapsed Platinum-Resistant Ovarian Cancer. https://clinicaltrials.gov/study/NCT05145218 |
| [60] | NCT (2022) Efficacy and Safety of TQB2450 Combined with Chemotherapy ± Anlotinib for Advanced Endometrial Cancer. https://clinicaltrials.gov/study/NCT05481645 |
| [61] | Sun, S., Qiu, H., Yang, H., Yang, C., Chen, M., Mei, Z., et al. (2022) Anlotinib plus Chemoradiotherapy in the Treatment for FIGO Stage IB3 and IIB-IVA Cervical Cancer: A Prospective Single-Arm, Single-Center, Exploratory Phase II Trial (299). Gynecologic Oncology, 166, S157. https://doi.org/10.1016/s0090-8258(22)01520-7 |
| [62] | Wang, H., Shan, B. and Tian, W. (2022) Anlotinib in Patients with Recurrent Platinum-Resistant or Platinum-Refractory Ovarian Carcinoma: A Prospective, Single-Center, Single-Arm, Phase II Clinical Trial (033). Gynecologic Oncology, 166, S23. https://doi.org/10.1016/s0090-8258(22)01251-3 |
| [63] | Wu, X., Liang, S., Chen, X., Hou, J., Wang, K., Wang, D., et al. (2022) 555P TQB2450 Injection Combined with Anlotinib Hydrochloride Capsule in the Treatment of Advanced, Recurrent or Metastatic Endometrial Cancer: A Multicohort, Open Label, Multicenter Phase II Clinical Trial—The TQB2450-II-08 Trial. Annals of Oncology, 33, S802. https://doi.org/10.1016/j.annonc.2022.07.683 |
| [64] | Wang, X., Li, J., Zhang, P., Fang, X., Wang, Y. and Sun, H. (2022) Anlotinib plus Letrozole in Patients with Platinum-Resistant Recurrent Ovarian Cancer: A Prospective, Single-Arm, Open-Label, Phase II Study. Journal of Clinical Oncology, 40, e17545. https://doi.org/10.1200/jco.2022.40.16_suppl.e17545 |
